Select Medical (NYSE:SEM – Get Free Report) is anticipated to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $1.3973 billion for the quarter. Select Medical has set its FY 2026 guidance at 1.220-1.320 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, July 31, 2026 at 9:00 AM ET.
Select Medical (NYSE:SEM – Get Free Report) last announced its earnings results on Thursday, April 30th. The health services provider reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.07). Select Medical had a return on equity of 6.62% and a net margin of 2.42%.The company had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.41 billion. During the same quarter last year, the firm posted $0.44 earnings per share. The firm’s revenue was up 5.0% on a year-over-year basis. On average, analysts expect Select Medical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Select Medical Stock Performance
NYSE SEM opened at $16.51 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.15 and a debt-to-equity ratio of 0.88. The stock’s 50-day simple moving average is $16.54 and its two-hundred day simple moving average is $16.12. Select Medical has a twelve month low of $11.65 and a twelve month high of $16.99. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 0.95 and a beta of 1.01.
Select Medical Announces Dividend
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on SEM. Weiss Ratings upgraded Select Medical from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, June 4th. Zacks Research upgraded shares of Select Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Mizuho reissued a “neutral” rating and set a $16.50 price target (down from $17.00) on shares of Select Medical in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $15.50.
View Our Latest Research Report on SEM
Hedge Funds Weigh In On Select Medical
Large investors have recently bought and sold shares of the stock. Graham Capital Management L.P. bought a new position in shares of Select Medical in the fourth quarter worth approximately $154,000. Brooklyn Investment Group bought a new stake in Select Medical during the 4th quarter valued at $161,000. CIBC Bancorp USA Inc. purchased a new stake in Select Medical during the 3rd quarter valued at $153,000. iSAM Funds UK Ltd purchased a new stake in Select Medical during the 3rd quarter valued at $96,000. Finally, Entropy Technologies LP bought a new stake in Select Medical in the 3rd quarter worth $177,000. 89.48% of the stock is owned by hedge funds and other institutional investors.
About Select Medical
Select Medical is a leading provider of specialized healthcare services in the United States, operating through two primary business segments: Hospital Division and Outpatient Rehabilitation Division. The Hospital Division offers long-term acute care (LTAC) hospitals and inpatient rehabilitation facilities (IRFs) that serve patients recovering from complex illnesses, trauma or surgery. The Outpatient Rehabilitation Division delivers physical, occupational and speech therapy services through a network of clinic locations and home-based care programs.
Headquartered in Mechanicsburg, Pennsylvania, Select Medical was founded in 1996 and has grown through strategic partnerships, joint ventures and acquisitions.
Further Reading
- Five stocks we like better than Select Medical
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Select Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Select Medical and related companies with MarketBeat.com's FREE daily email newsletter.
